|
|
Speakers 
Dr Mark Abdy,
Veterinary Medical Officer,
FDA-CBER
Mark Abdy is a veterinary medical officer in the Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. He graduated from the University of Georgia College of Veterinary Medicine in 1992 and worked in a mixed animal veterinary practice in South Carolina. He then returned to the University of Georgia and completed a veterinary anatomic pathology residency and Ph.D. in veterinary pathology in 1997. Following graduate school, he joined the faculty at the University of Florida College of Veterinary Medicine where he managed an equine influenza vaccine trial for 3 years. In 2000 he was selected as the American Veterinary Medical Association Congressional Science Fellow and spent his fellowship year working on bioscience issues for Congressman Sherwood Boehlert. In September 2001 he was hired as a professional staff member for the House Committee on Science where he worked primarily on public health issues for Chairman Boehlert. He joined the Office of Vaccines Research and Review in CBER in June 2002, and works primarily on issues pertaining to the “Animal Rule”.
|
Dr Peter Andersen,
Director, Department of Infectious Disease Immunology,
Statens Serum Institut
|
Mr KV Balasubraniam,
Managing Director,
Indian Immunologicals Limited
|
 Dr Steven Bell,
VP - Research & Pre-Clinical Development,
BioSante Pharmaceuticals, Inc
Dr. Bell graduated from Rhodes University in 1981, studied Medicine at University of Cape Town, did graduate studies at the University of Bern,Switzerland, then did a PhD at University of New South Wales, Sydney. He also holds a MBA from KSU, Georgia.
Dr. Bell has worked in different capacities for Boehringer Mannheim, Hoffmann-La Roche, The Upjohn Company, Boehringer Ingelheim, and has been with BioSante Pharmaceuticals since 1997 where he is VP, Research & Pre-clinical Development.
|
 Dr Jean-Yves Bonnefoy,
Chief Scientific Officer,
Transgene S.A
Jean-Yves BONNEFOY, Vice-President, Research, was appointed Vice President, Research in february 2005. Prior to joining Transgene, he was Head of the Canceropôle Lyon Rhônes-Alpes. From 1997 to 2002, he was Director of the Immunology Center of the Pierre Fabre Group in Saint-Julien en Genevois, France. He previously was responsible for the Immunology Department of the Biomedical Research Institute of the Glaxo-Wellcome Group in Geneva, Switzerland. Jean-Yves Bonnefoy holds a PhD in immunology from the Lyons Claude Bernard University and has completed the Senior Management Program of the London Business School.
|
Dr Jeff Brady,
Medical Officer,
FDA
Jeff Brady is a medical officer and clinical reviewer in the Division of Vaccines and Related Products Applications, Food and Drug Administration. He attended the Medical College of Georgia, completed internship training in the Department of Internal Medicine at the Naval Medical Center, San Diego, California, and studied public health at the Uniformed Services University of the Health Sciences (USUHS), in Bethesda, Maryland. In July 2000, he completed the Navy’s General Preventive Medicine Residency, also at USUHS. Dr. Brady has served as the department head and general medical officer, aboard the USS Coronado, and, later, as a medical epidemiologist. In July 2002, he transferred from the Navy to the Commissioned Corps of the U.S. Public Health Service and entered his current position. He is board-certified in Public Health and General Preventive Medicine.
|
 Dr Crawford Brown,
Chief Executive Officer,
Eden Biodesign
Crawford is CEO of Eden Biodesign (contract development and manufacturing services) and leads Eden Biopharm consulting services now established one of Europe’s largest and most successful specialist biopharmaceutical technical-regulatory consultancies.
In 2004 Eden raised £5m equity capital from an investment syndicate led by Stephens Inc, the largest privately held investment banking firm outside of Wall Street. Additionally, Eden successfully won the European-wide UK government tender to lease and operate the UK National Biomanufacturing Centre a £30 million project sponsored by the North West Development Agency, the European Regional Development Fund and the UK Department of Trade and Industry.
Crawford has been involved with the Biotech sector for over 20 years having held senior positions in product development at Celltech-Medeva Pharma (Liverpool), British Biotech (Oxford) and Wellcome Biotech (Beckenham, Kent). At Medeva, as Director of Product Development, he established one of the UK’s largest product development teams that were the first in the UK to take a recombinant vaccine from the laboratory through to approval by the European Medicines Control Agency (EMEA).
Crawford qualified from Strathclyde University with a BSc in Applied Microbiology and a PhD in Chemical and Process Engineering. He is a Senior Visiting Lecturer on Modular Training for the Bioprocess Industries (MBI) course at the Advanced Centre for Biochemical Engineering. University College, London.
Crawford has completed assignments over the past five years in Denmark, Germany, Switzerland, Netherlands, Australia, India, Japan, South Korea, Taiwan and the USA. The focus of assignments is exclusively biopharmaceutical development including therapeutic and prophylactic vaccines, monoclonal antibodies, gene therapy and stem cell/tissue engineered products.
|
 Dr Michael Buschle,
Chief Technical Officer,
Intercell
Michael Buschle, who also cofounded Intercell, is Chief Technical Officer and Head of Industrial Operations at Intercell as well as Managing Director of Intercell Biomedical Ltd.
His scientific and industrial career includes work at the Royal Free Hospital School of Medicine, London, UK, the St. Jude Children's Research Hospital, Memphis, TN, USA and at the pharmaceutical company Boehringer Ingelheim. During his time at Boehringer Ingelheim, he was involved in the development of a cancer vaccine against malignant melanomas. Michael Buschle is the holder of several patents in the field of vaccines and biotechnology.
At Intercell, his responsibilities include manufacturing, process development, production and quality.
|
 Mr Kim Bush,
President, Vaccines SBU,
Baxter Healthcare Corporation
Kim Bush joined Baxter International in 1978 and currently holds the position of President, Baxter BioScience, Vaccines Division. He and his team are responsible of the commercial management of Baxter’s vaccine business on a global basis. Prior to holding this position, Kim held several Baxter senior management positions including, President, Hyland Immuno Europe, President, Biotech Europe and President of Baxter’s Fenwal Division. Prior to the spin-off of Allegiance from Baxter, Kim also served as President for both the Industrial and Life Sciences Division and the Biomedical Division of Allegiance Healthcare Corporation.
|
Dr Stephen Chatfield,
Chief Scientific Officer,
Emergent Biosolutions
Steve is currently Chief Scientific Officer for Emergent BioSolutions, a US company focused on the Research, Development and Manufacturing of vaccines. In this role he has the responsibility for R&D strategy and for the development of the vaccine technologies and products.
Steve has spent over 25 years working in the field of vaccine research and development within Industry, previously working at Microscience Ltd, Medeva plc, Evans Medical and Wellcome Biotechnology. He has had a wide range of experience and responsibilities encompassing all phases of vaccine development, including research, process and analytical development, toxicology, GMP manufacture, regulatory submissions and clinical studies in both Europe and the US, including compilation and submission of MAA and BLA dossiers. He has also written expert reports in support of regulatory submissions.
His research efforts have focused on the molecular basis of pathogenicity of bacterial and viral infections. Much of this work has been directed towards the development of novel vaccines and immunotherapeutics, particularly those that can be delivered by the mucosal route. He has published over 97 papers in this field, written several book chapters and is regularly invited to speak at international meetings on Vaccine R&D.
|
Dr Jo Cohen,
Director, Emerging Diseases, HIV and Therapeutic Vaccines,
GlaxoSmithKline Biologicals
|
 Prof Angus Dalgleish,
Research Director,
Onyvax
Angus Dalgleish was appointed to the Foundation Chair in Oncology at St. George’s Hospital Medical School in 1991. He is the Founding Director of Onyvax, a cancer vaccine company since 1998, where he is currently Research Director.
His main interests include the optimisation of adjuvant and cell-based vaccines for solid tumours, immunostimulatory and anti-angiogenic small molecules and the pathogenesis of AIDs. He is on the Scientific Advisory Board of Progenics, Celgene and Onyvax.
He has edited five books and authored over two hundred and sixty original papers, as well as appearing in, and consulting to, programmes on HIV and cancer for Horizon, Discovery, etc.
He obtained his MB BS with an intercalated BSc and MD from the University of London. He is a Fellow of The Royal College of Physicians of the U.K. and Australia, Royal College of Pathologists and The Academy of Medical Scientists.
|
 Mr Gwyn Davies,
Director, Research & Development,
OM Pharma
Gwyn Davies is currently Head of R&D Projects and Partnerships at OM PHARMA in Geneva and as such is responsible for establishing strategic partnerships for the development of OM PHARMA’s adjuvants in vaccines. Dr. Davies obtained his MA and D.Phil at the University of Oxford, specialising in protein chemistry under the supervision of Robin Offord. He moved to the Department of Medical Biochemistry at Geneva University in 1980 and from there joined OM PHARMA in Geneva 1991. At OM PHARMA he has been responsible for novel adjuvant discovery, OM?-174 and the OM?-Triacyl family of synthetic adjuvants, and has been directly involved with the adjuvant programme from the bench to GMP manufacture and clinical trial. Dr Davies is also a founder member of the European Adjuvant Advisory Committee and holds the post of Honorary Senior Lecturer at St. George’s Hospital Medical School in London.
|
Dr Menno De Jong,
Clinical Virologist,
Hospital for Tropical Diseases Viet Nam
|
 Mr Jan Dheedene,
Production Development Manager,
Federa S.A, a Cardinal Health Company
Training :
- industrial pharmacy – University of Gent Belgium
- Special License in Pharmaceutical Engineering
- Career
- 1988- 1990 : University Ghent : Assistant in the Toxicology Department with focus on clinical toxicology
1990 -1998 : Federa (now part of Cardinal Health) : Production Manager : management of compounding, filling and secondary packaging departments of injectable products in ampoules and pre-filled syringes .
- 1998-now : Federa – Cardinal Health Brussels : Production Development Manager : coordination and project management of all new customer projects of Cardinal Health Brussels as contract manufacturing organization for injectable drug products. This includes project evaluation, coordination of technical transfer,, and global project management.
|
Nathalie Garcon,
Director,Research and New Technologies,
GlaxoSmithKline Biologicals
|
 Dr Gregory Glenn,
Senior Vice President and Chief Scientific Officer,
Iomai
Gregory Glenn is the Chief Scientific Officer of IOMAI Corporation in the Washington DC area, and a recognized thought leader in the field of vaccine delivery. Dr. Glenn trained as a research scientist at the Walter Reed Army Institute of Research, where he focused on vaccine delivery of adjuvants and made early observations regarding delivery of vaccines to the skin. He and his colleagues have published over 30 articles relating to skin delivery of vaccines. He founded IOMAI in 1997 and has led the development of the technology from the first preclinical data to Phase 2 efficacy trials. He received his B.A. degree from Whitman College and M.D. at Oral Roberts University, was Board Certified in Pediatrics and completed the Medical Research Fellowship at the Walter Reed Army Institute of Research. Dr. Glenn is also an Associate Professor at the John Hopkins School of Public Health in Baltimore. His current interests include traveler’s diarrhea, influenza and pandemic influenza, and biodefense vaccines.
|
Reinhard Gluck,
Director of Research and Development,
Berna Biotech
|
 Dr Lance Gordon,
President and CEO,
VaxGen
Dr Lance Gordon has more than 20 years of experience in the vaccine industry, developing both vaccine products and companies. Prior to joining VaxGen, Dr Gordon served as founding CEO and a member of the Board of Directors of two vaccine companies, OraVax and North American Vaccines. He was also the CEO of North American’s predecessors, American Vaccine Corp and Selcore, Inc. During the 1980’s, Dr. Gordon served a seven-year tenure at Connaught where he was Director of Viral and Bacterial vaccines research and the inventor of ProHibit® a vaccine for infant meningitis, the first bacterial conjugate vaccine to receive FDA approval. After leaving Connaught, he served as a medical director at E.R. Squibb where he designed and implemented clinical pharmacology programs for infectious and inflammatory disease products and candidates.
|
 Jaap Goudsmit,
Chief Scientific Officer,
Crucell NV
As per March 2002 Jaap Goudsmit is affiliated with Crucell, a leading biotechnology company in Leiden. He started as Senior Vice President Vaccine Research. In July 2002 he accepted the position of Chief Medical Officer and became a member of the Executive Committee as Executive Vice President Vaccine Research and Development. Since September 2002 he holds the position of Chief Scientific Officer and Head Research and Development. In January 2004 he became a member of Crucell's Management Board.
In August 2003 Jaap Goudsmit accepted his appointment as chairman of the board of the AIDS Foundation East-West, an NGO focused on AIDS prevention in the countries of the former Soviet Union.
In December 2003 Jaap Goudsmit has been elected as member of the HIV Vaccine Enterprise Product Development Working Group of the Gates Foundation.
|
 Mr Michel Greco,
Independent Vaccine Expert,
Independant Vaccine Expert
Michel Greco has had a long and successful career in the industry, both in pharmaceuticals first, with the former Rhone-Poulenc Group, and in the vaccine area for the last 15 years. From 1988 to 1993, through successive mergers and acquisitions, he had senior management responsibilities at Institut Mérieux, then Pasteur Mérieux Connaught. From 1994 to 1998, he was President and CEO of Pasteur Mérieux MSD (a European joint venture between Pasteur Mérieux and Merck). Since 1998 and until the beginning of 2003, he was President and COO, then Deputy CEO and member of the Board of Aventis Pasteur. Michel Greco is presently member of the Board of a number of biotechnology companies and of non-profit international institutions.
|
Dr Luc Hessel,
Executive Director, Medical & Public Affairs,
Sanofi Pasteur Ltd
|
Dr Howard Kaufmann,
Vice Chairman, Surgical Oncology,
New York Presbyterian Hospital - Columbia Campus
Dr. Kaufman is an academic surgical oncologist and has an active interest in tumor immunology. His laboratory is focused on tumor vaccine development and murine models of human cancer. He is board certified in Surgery and is the Director of the Interleukin-2 (IL-2) unit located at the Milstein Hospital of Columbia Presbyterian Medical Center. He also is the Director of the Columbia University Melanoma Center. Dr. Kaufman is the Associate Director of the Herbert Irving Comprehensive Cancer Center and holds numerous academic and hospital appointments, including Vice Chairman for Surgical Oncology, Associate Professor of Pathology and Clinical Surgery at the College of Physicians and Surgeons of Columbia University. He has been funded by the National Institutes of Health, American College of Surgeons, Howard Hughes Medical Institute, and was the first Doris Duke Clinical Scientist awardee for cancer in 1998. He chairs the Immunomolecular Therapeutics Committee of the Southwest Oncology Group and is on the editorial board of several scientific journals. Dr Kaufman is a member of many professional societies, including the American College of Surgeons, Manhattan State Chair for the Commission on Cancer, Society of University Surgeons, Society of Surgical Oncology, American Society of Clinical Oncology, the New York Academy of Sciences, The Harvey Society, The Society for Melanoma Research and the American Association of Cancer Research. He is a member of the steering committee for the New York State Cancer Control Plan.
|
Mark Kendall,
Associate Director,
Medical Engineering University of Oxford
|
Wayne Koff,
Vice President,
The International AIDS Vaccine Initative
Dr. Wayne C. Koff, Sr. Vice President and Chief of Vaccine Research at the International AIDS Vaccine Initiative (IAVI) in New York City, is an internationally recognized viral immunologist in the field of AIDS vaccine research and development. Dr. Koff has been honored twice by the U.S. Department of Health and Human Services with the Special Act of Service Award for developing innovative strategies for accelerating global efforts in AIDS vaccine development. At IAVI, Dr. Koff focuses on addressing the major scientific challenges currently impeding AIDS vaccine development, and oversees IAVI’s research agenda to identify the next generation of promising vaccine concepts. Since joining IAVI in 1999, Dr. Koff's has led IAVI's programs to develop four vaccine technologies and five vaccine candidates from concept to clinical trials. Between 1992-1998, he served as Vice President, Vaccine Research and Development, at United Biomedical, Inc. (UBI), where he was responsible for its vaccine R&D program. During his tenure at UBI, the company conducted the first AIDS vaccine clinical trials in the developing countries of the People's Republic of China, Thailand, and Brazil. Between 1988-1992, he served as Chief of the Vaccine Research and Development Branch, Division of AIDS, at the National Institute of Allergy and Infectious Diseases (NIAID), where he led the team that established the preclinical and clinical AIDS vaccine development programs for the National Institutes of Health (NIH). An Adjunct Professor in the Department of Microbiology at the State University of New York, Stony Brook, Dr. Koff has published more than 70 scientific papers and edited five books on vaccine development. He received his B.A. from Washington University and his Ph.D. from Baylor College of Medicine
|
 Dr Reiner Laus,
Founding CEO and President,
Dendreon
Dr. Laus is founding CEO and President of BN ImmunoTherapeutics, which was formed as a member of the Bavarian Nordic group in January, 2005. BN ImmunoTherapeutics focuses on the development of recombinant Modified Vaccinia Ankara (MVA) for the immunotherapy of cancer. Prior to this, Dr. Laus held the position of Vice President of Research and Development at Dendreon Corporation, where he worked since 1993. Dendreon is a Seattle-based developer of cancer immunotherapies. Previously, Dr. Laus held research appointments at the University of Kiel, Germany and at Stanford University in California. Dr. Laus received his M.D. from the University of Kiel in 1986.
|
Jose Lebron,
Research Fellow, Department of pre-clinical Safety Assessment,
Merck Research Laboratories
|
Mr Gregory Levine,
Parnter,
Arnold and Porter LLP
Greg Levine is a partner in Arnold & Porter LLP’s Pharmaceutical and Medical Device group. His practice focuses on providing regulatory and compliance counseling to U.S. and multinational pharmaceutical, biotechnology, cosmetics, and medical device companies. Mr. Levine has advised clients in regulatory and compliance matters covering all aspects of the product life cycle. He also has assisted clients in responding to government investigations and enforcement actions and helped clients negotiate and draft consent decrees and other settlements with the FDA, the U.S. Department of Justice, and state Attorneys General. In addition, he has prepared expert witnesses and helped negotiate, draft, and implement settlements in major product liability litigation cases involving pharmaceuticals and medical devices.
Prior to joining Arnold & Porter LLP, Mr. Levine was a legislative staff member in the U.S. House of Representatives and a member of a White House task force on health care reform. Mr. Levine received his J.D. magna cum laude from the Georgetown University Law Center in 1996 and an A.B. magna cum laude from Brown University in 1990.
|
 Dr Julian Lob-Levyt,
Vaccine Fund Chief Executive Officer and GAVI Executive Secretary,
The Vaccine Fund
Julian Lob-Levyt is GAVI’s Executive Secretary and Chief Executive Officer of The Vaccine Fund
Lob-Levyt brings a wealth of experience to the GAVI Alliance — both from his work at the international health policy level and from his extensive work in developing countries. Prior to this, Lob-Levyt, a UK national, worked for UNAIDS as Senior Policy Adviser to the Executive Director, Peter Piot. Before that appointment, Lob-Levyt was the Chief Health and Population Adviser (latterly Chief Human Development and Health Adviser) at the UK Department for International Development (DFID), with overall policy responsibility for health, population and HIV. Lob-Levyt represented the UK Government and donor constituencies as a member of the GAVI Board. He also represented the UK as a founding board member of the Global Fund to Fight TB, AIDS, and Malaria and has been involved in the provision of bi-lateral support to a range of public-private health initiatives such as the International AIDS Vaccine Initiative (IAVI) and the International Microbicides Partnership, as well as WHO programmes including Roll Back Malaria, STOP TB, and the lymphatic filariasis and guinea worm programmes. He was also closely involved in the work of the WHO Commission on Macroeconomics and Health, which reported in December 2001.
|
 Dr Jill Makin,
Vice President Research and Development, Emergent Europe,
EMERGENT EUROPE LIMITED
Jill has worked in the biotechnology industry for 15 years, for Microscience Ltd, Celltech, Medeva PLC and Evans Vaccines. Her experience has primarily been in prophylactic and therapeutic vaccines, where she has gained her working knowledge of the vaccine industry, from laboratory research through clinical development, product licensure, product launch and commercial supply. In R&D she has held positions with functional responsibility for all stages of vaccine development in US and Europe, including process and analytical development, pre-clinical pharmacology and safety testing, GMP manufacture, regulatory affairs, clinical development and project management.
|
Dr Trevor Marks,
Business Development Manager,
Health Protection Agency Porton Down
|
 Mr Jacques-Francois Martin,
President and CEO,
Parteurop
Jacques-François Martin has spent the essence of his career in the pharmaceutical, biological and life sciences industries.
From 1970 until 1976, he was the Chief Executive Officer of Rhône-Poulenc Pharma in Hamburg, Germany. Martin then returned to France to join the Institut Mérieux as Vice President of sales and marketing, where he largely contributed to the international expansion of Mérieux. He was named the company’s Chief Executive Officer in 1988, and successfully negotiated with the government of Canada to acquire Connaught Laboratories.
In 1991, Martin set up Parteurop S.A, a biotech consulting company based in Lyon, France. At Parteurop, Martin as Chairman and CEO, helps establish start-up companies by leveraging innovation from French and foreign institutions.
From 1996 to 1998, Martin was the Chief Executive Officer of the Fondation Jean Dausset – Centre d’Etudes du Polymorphisme Humain, a private foundation dedicated to genomics research.
From September 1996 to September 1999, he was a member of the Board of INSERM (Institut National de la Santé et de la Recherche Médicale, the French National Institute of Health).
From 1994 to 1997, Martin served as the Chairman of the Biologicals Committee of the International Federation of Pharmaceutical Manufacturers Associations. As such, he was a member of the Scientific Advisory Group of Experts of WHO (SAGE).
From November 1997 to June 2003 he was a member of the Board of the International AIDS Vaccine Initiative (IAVI).
From 2000 to January 2005, Martin held the position of President of The Vaccine Fund. He lead the Fund’s efforts to provide lifesaving vaccines and other immunization program support to low-income countries. In this capacity, he was also a member of the Board of GAVI (Global Alliance for Vaccines and Immunization).
He is member of the Board of several life sciences companies. Martin holds a Master’s in Business Administration from the Ecole des Hautes Etudes Commerciales.
|
Eszter Nagu,
Head of Pre Clinical Research,
Intercell
|
 Dr Ronald Neeleman,
Manager Influenza Vaccine Development,
Solvay Pharmaceuticals
Dr. R. Neeleman received his PhD in biotechnology at the Wageningen University (The Netherlands) in 2002. Before that he worked as a bioprocess engineer at the National Institute of Public Health and the Environment in The Netherlands. After receiving his PhD, he stayed at the National Vaccine Institute in Bilthoven, The Netherlands (working at the development of vaccines against whooping cough and meningitis). Dr. R. Neeleman joined Solvay Pharmaceuticals in 2003 and became Manager of Influenza Vaccine Development in 2004.
Currently
In his current position as Manager of Influenza Vaccine Development he is, amongst others, responsible for the animal cell technology and a whole range of programs, from virosomal vaccines and cell mediated immunity to alternative routes of administration and pandemic preparedness.
Publications
Dr. R. Neeleman is author and co-author of a broad range of biopharmaceutical publications in peer reviewed scientific journals.
|
 Dr Klaus Neurohr,
Head of Quality and Regulatory Affairs,
Avecia Biotechnology
Qualification:
PhD in Chemistry Justus Liebig University, Giessen, Germany 1982, Research for PhD carried out in the Division of Biological Sciences, National Research Council of Canada, Ottawa.
Experience:
Eighteen years of experience in the Pharmaceutical/Biotechnology industry, primarily with major international corporations (Aventis, Schering AG) and a CMO. Experience encompasses Research, Development, Manufacturing, Project Management, Business Management, Quality and Regulatory Affairs.
Ca. 6 years academic experience (post PhD) at the Lund Institute of Technology, Lund, Sweden, Yale University, New Haven, Connecticut, MIT, Cambridge, USA and the German National Cancer Centre, Heidelberg, Germany.
Current position: Head of Quality & Regulatory Affairs, Avecia Biologics. Member of Avecia Biologics Board.
Strategic direction and leadership of the Quality Unit of the Biologics business, consisting of QA, QC and Regulatory Affairs departments, also involved in Avecia-wide Quality Leadership activities. Member of Business and Customer Project Steering Teams.
Involved in Avecia Biologics CMO business supporting a number of phase 1, phase 2 and phase 3 clinical manufacturing projects for several US and EU customers with the intent of taking projects into commercial manufacture.
Also involved in Biodefence vaccine business currently focussed on Anthrax and Plague vaccine development programmes, where Avecia leads international consortia and intends to take products to licensure in the US and EU.
|
 Dr Richard Nolan,
Senior Advisor to the Director, Strategic National Stockpile,
CDC
|
Dr JM Okwo-Bele,
Medical Officer,
WHO
I have been working in public health for 24 years, including 10 years with the Ministry of Health of DR Congo, my home country; 12 years with the Regional Office of WHO in Africa, supporting and, later, coordinating its immunization programme; two years with UNICEF New York as Team Leader for immunization plus activities. In August 2004, I joined WHO in Geneva as the Director of the Department of Immunization, Vaccines and Biologicals. The Department oversees WHO global immunization activities, which include the Initiative for Vaccines Research and Development, setting norms and standards for vaccines and immunization-related equipment, vaccines regulatory activities and supporting national immunization programmes for increasing access and coverage and monitoring progress and impact on the reduction of vaccine preventable diseases.
I hold a medical degree from the University of Kinshasa and a Master's degree in Public Health from the Johns Hopkins School of Public Health and Hygiene.
|
 Dr Bram Palache,
Global Medical Affairs Director, Influenza Vaccine,
Solvay Pharmaceuticals
1973-1980: University of Amsterdam, Biochemistry (MSc degree)
1980-1984: Clinical Research Associate. Clinical Research Department Duphar B.V., Weesp, The Netherlands
1984-1987: European Clinical Projectleader, Gastroenterology group. Clinical Research Department Duphar B.V., Weesp, The Netherlands
1984: International Clinical Projectleader, Influenza vaccine. Clinical Research Department Duphar B.V., Weesp, The Netherlands
1990-1991: Influenza Research Fellow at Erasmus University and the WHO Dutch National Influenza Centre, Rotterdam, The Netherlands (Prof N. Masurel)
1991: Thesis and PhD degree, Erasmus University, Rotterdam, The Netherlands (Prof N. Masurel)
1990: Global Medical Affairs Director Influenza Vaccines. Solvay Pharmaceuticals B.V., Weesp, The Netherlands
1990: Board Member of "Foundation of Respiratory Virology, in particular Influenza (SRVI)", Erasmus University and WHO Dutch National Influenza Centre, Rotterdam, The Netherlands (Chairman: Prof. A.D.M.E. Osterhaus)
Since 1992: Executive Board member, European Scientific Working group on Influenza (ESWI)
Since 1993: Editorial Board member, "Influeza", Bulletin of European Scientific Working group on Influenza (ESWI)
Since: 2000Member of the Organising Committee Options IV Meeting Crete, Greece.
Since 2001: Members of the Clinical Working Group EVM (European Vaccine Manufacturers)
Since 2001: Member of the Public Health Working Group EVM (European Vaccine Manufacturers)
Since 2002: Member of the Organising Committee First European Influenza Conference, Malta
|
 Dr Helene Pora,
Vaccine Application Development Director,
Pall Life Sciences
Dr Hélène Pora is Vaccine Application Development director with Pall LIfe Sciences , where she has the worldwide responsibility for the development of improved separation and purification solutions for the vaccine and gene therapy market. She is also heavily involved in the development of improved single use technologies and related scale-up aspects. Hélène has more than 20 years of experience working for the pharmaceutical and the separation industries, the last 15 years with Pall Corporation. She holds an Engineering Degree in Biochemistry (with Molecular Biology) from the Institut National Agronomique (France) and a PhD in Biochemistry ( on protein engineering and purification) from the University of Orsay (France). Hélène Speaks regularly at conferences about improved separation technologies for the biotechnology and biopharmaceutical industry.
|
Charles Proby,
VP Business Development, Biotech & Sterile Life Sciences,
Cardinal Health
|
 Dr Una Ryan,
President and CEO,
Avant Immunotherapeutics
Una S. Ryan, Ph.D., O.B.E., is President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., a publicly traded Massachusetts biotechnology company developing vaccines for large high value markets including cholesterol management, infectious diseases, biodefense and food safety; AVANT’s partner GSK has initiated Phase III trials of its RotarixÒ rotavirus vaccine, and AVANT is working on several funded biodefense vaccine development contracts including an oral single-dose combination anthrax/plague vaccine and developing its VitriLife® preservation process to produce temperature-stable single-dose live oral vaccines. Dr. Ryan is Research Professor of Medicine at the Whitaker Cardiovascular Institute, serves on the Board of the Biotechnology Industry Organization and the Whitehead Institute Board of Associates, and is 2004-2006 Chair of the Massachusetts Biotechnology Council. From 1990 to 1993 she held the position of Director of Health Sciences at Monsanto Company and was Research Professor of Surgery, Medicine and Cell Biology at Washington University School of Medicine. Dr. Ryan was Professor of Medicine at the University of Miami from 1980 to 1989 and Chief, Division of Vascular Cell Biology from 1986 to 1989. In 2002 Her Majesty Queen Elizabeth II awarded Dr. Ryan the Order of the British Empire (OBE) for her services to research, development and promotion of biotechnology.
|
 Philippe Stas,
Chief Operating Officer,
AlgoNomics
|
 Dr Klaus Stohr,
Coordinator, Global Influenza Programme,
WHO
|
 Dr. Frederic Triebel,
Scientific and Medical Director,
Immutep S.A.
Pr. Frédéric TRIEBEL is a founder and the Scientific and Medical Director of Immutep S.A.. He received his M.D. degree in 1981, was trained as a clinical haematologist and obtained his Ph.D. in Immunology in 1986. He was nominated Professor in Immunology in 1990 at the Paris-Sud University and worked for 16 years at Institut Gustave Roussy (IGR) where he conducted basic science and clinical research. He discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical usefulness of this molecule in the field of therapeutic vaccines. He was Director of an INSERM Unit from 1991 to 1996 at IGR and successfully developed several research programs in immunogenetics, leading to 125 publications.
|
 Mr Jim Turner,
Partner,
Arnold and Porter LLP
Areas of Expertise:
National Security Law and Policy
Public Policy and Legislative
Congressional Oversight
Jim Turner, former Congressman, is a Partner in the national security and public policy and legislative practices.
Before joining the firm, Congressman Turner was the Democratic representative for Texas' 2nd Congressional District in the U.S. House of Representatives from 1997 until 2005. Congressman Turner was a member of the Armed Services Committee and was the ranking member of the House Select Committee on Homeland Security. He was also a Co-Chair of the Blue Dog Coalition, a group of pro-business Democrats in the U.S.House.
In the 108th Congress, Congressman Turner was named the top-ranking Democrat on the newly formed Committee on Homeland Security. Turner, a Vietnam-era Army veteran, was the top Democrat on the Terrorism Panel that the Armed Services Committee created after the Sept. 11, 2001 attacks on the World Trade Center and the Pentagon. Turner also served as the ranking Democrat on the Government Management, Information, and Technology Subcommittee of the House Government Reform Committee and as the second-ranking Democrat on the Armed Services Committee's new Terrorism and Unconventional Threats Panel.
Prior to being elected to Congress, Congressman Turner held several state and local offices and served under four former Governors of Texas. Following graduation from the University of Texas School of Law, Turner served as a briefing attorney for the Texas Supreme Court. He was a member of the Texas House of Representatives from 1981–1984, mayor of Crockett, Texas from 1989–1991, and a member of the Texas State Senate from 1991–1996. He served as Chief Legislative Liaison and Chief of Staff to Texas Governor Mark White from 1985 to 1987. Turner was elected representative for Texas' 2nd Congressional District in the U.S. House of Representatives in 1996, taking office in 1997.
*Admitted only in Texas; practicing law in the District of Columbia pending approval of application for admission to the D.C. Bar and under the supervision of principals of the firm who are members in good standing of the D.C. Bar.
Admitted
Texas
Presentations
Speech: The Future of Medicare in a Growing Fiscal Storm (PDF: 24.5 KB), Jim Turner, Registries & Post-Marketing Data Collection Seminar
Education
M.B.A., University of Texas, 1971
J.D., University of Texas School of Law, 1971
B.B.A., University of Texas, 1968
U.S. Army Reserve, 1970-1978
|
 Prof Alexander von Gabain,
Chief Executive Officer,
Intercell
Alexander von Gabain is Intercell’s co-founder and Chief Executive Officer. Previously, he was the Chairman of the Department of Microbiology and Genetics at the renowned Vienna Biocenter/IMP research campus. Alexander von Gabain’s scientific career has taken him to outstanding institutions such as the University of Heidelberg and the University of Stanford as well as to the Nobel Karolinska Institut in Stockholm, where he served as a professor of medical biotechnology and later as a foreign adjunct professor. Alexander von Gabain is a member of numerous professional organizations, co-publisher of scientific journals and has established a range of worldwide contacts through his work as a consultant to pharmaceutical companies as well as by organizing prestigious conferences. At Intercell, his responsibilities include to chair the board of directors, to overview the strategic decisions and processes and to chair the supervisory board of the Intercell spin off Biovertis.
|
John Wecker,
ADIP Director,
PATH
|
|
|
|
